In a recent transaction, Sheena Jonathan, co-founder of Natera, Inc. (NASDAQ:), a leading personal genetic testing and diagnostics company, sold a significant amount of the company’s stock. The total sale, which took place on September 18, 2024, was more than $2.8 million.
The transactions involved the sale of several blocks of shares at varying prices. The prices per share in these transactions ranged from $127.3779 to $128.0748. In detail, the sales were made in multiple transactions, with the shares sold at different prices within the specified range. The total number of shares that Jonathan sold in a single block was not disclosed, but rather it occurred in multiple transactions as part of pre-agreed trading plans.
Jonathan adopted these trading plans, known as Rule 10b5-1 plans, on different dates, with some plans created as early as March 13, 2023, and others as early as December 12, 2023. Rule 10b5-1 plans allow company insiders to sell shares at pre-determined times to avoid insider trading charges.
It is worth noting that some of the shares sold were indirectly owned by trusts, Caraluna Trust 1 and Caraluna Trust 2, for the benefit of Jonathan’s minor children. Jonathan disclaimed beneficial ownership of these securities, stating that they were owned for the benefit of the children.
The sale represents a significant divestment by the co-founder, but Sheena Jonathan’s remaining holdings in Natera, Inc. remain significant. Following the sale, the exact number of shares held by Jonathan directly or indirectly through trusts is detailed in an SEC filing but is not provided in this summary.
Insider transactions are often watched by investors because they can provide insights into insiders’ views of a company’s current valuation and future prospects. However, such sales can also be part of standard financial planning and diversification strategies by company insiders.
Natera, Inc. continues to be a major player in the medical laboratory industry, providing innovative genetic testing solutions. The company’s business address is in Austin, Texas, and it operates under the jurisdiction of the State of Delaware.
In other recent news, Natera Company The company has been in the spotlight for several significant developments. The company reported a 12% sequential revenue increase from the first quarter and a 58% year-over-year increase, prompting it to raise its full-year revenue guidance to around $1.5 billion. The gross margin forecast is 55%, accompanied by a record number of test volumes and higher average selling prices.
Analysts from Piper Sandler, TD Cowen and Canaccord Genuity maintained positive ratings on Natera shares, highlighting the potential impact of the new Galaxy study results and the outlook for the European Society for Medical Oncology (ESMO) presentation. They emphasized Natera’s strong market leadership due to its leading advantages, particularly with its Signatera cancer test.
In other developments, Natera’s Renasight test received approval from the National Kidney Foundation to test for chronic kidney disease. Despite the delay in submitting the ALTAIR study and the non-renewal of the partnership with the Medicine Foundation, the company expects steady sequential growth in volumes and revenues with revenues projected to grow 40% versus 2023. Here are some recent highlights from Natera’s journey.
InvestingPro Insights
Following recent insider trading by Natera, Inc. (NASDAQ:NTRA) co-founder Shina Jonathan, investors are closely watching the company’s financial health and stock performance. According to InvestingPro data, Natera has a strong market cap of $15.75 billion, reflecting strong investor confidence in the company’s market position and future growth potential.
Despite not turning a profit in the past twelve months, Natera has shown impressive revenue growth, with recent figures showing a 46.13% increase in the past twelve months through Q2 2024. This growth trajectory is further evidenced by the company’s quarterly revenue growth of 58.13% in Q2 2024, indicating continued strong momentum in the business.
InvestingPro’s advice confirms that analysts have revised their earnings forecasts upward for the coming period, which could indicate continued revenue growth or operational improvements. Furthermore, Natera stock has seen a strong return over the past three months, with a total price return of 19.3%, and a remarkable return of 170.21% over the past year, demonstrating its strong performance in the stock market.
For investors looking for more in-depth analysis, additional InvestingPro tips are available, including insights into Natera’s liquidity, debt levels, and trading multiples. Currently, there are 9 more tips listed on InvestingPro that can help investors make more informed decisions about Natera, Inc. and can be found at: https://www.investing.com/pro/NTRA.
This article was created with the support of AI and reviewed by an editor. For more information, see our Terms and Conditions.